Expression of the AT2 receptor developmentally programs extracellular signal-regulated kinase activity and influences fetal vascular growth
Open accessThe DOI matches its Crossref record.
Abstract
Angiotensin II type 2 (AT2) receptor is abundantly expressed in vascular smooth muscle cells (VSMC) of the fetal vasculature during late gestation (embryonic day 15-20), during which the blood vessels undergo remodeling. To examine directly the influence of AT2 receptor expression in the developmental biology of VSMC, we studied cultures of VSMC from fetal and postnatal wild-type (Agtr2(+)) and AT2 receptor null (Agtr2(-)) mice. Consistent with in vivo data, AT2 receptor binding in cultured Agtr2(+) VSMC increased by age, peaking at embryonic day 20, and decreased dramatically after birth. Angiotensin II-induced growth in Agtr2(+) VSMC (embryonic day 20) was increased by the AT2 receptor blocker PD123319, indicating that the AT2 receptors are functional and exert an antigrowth effect in Agtr2(+) VSMC. Growth of VSMC in response to serum decreased age dependently and was higher in Agtr2(-) than in Agtr2(+), inversely correlating with AT2 receptor expression. However, serum-induced growth in Agtr2(+) and Agtr2(-) VSMC and the exaggerated Agtr2(-) VSMC growth was maintained even in the presence of PD123319 or losartan, an AT1 receptor blocker. Moreover, Agtr2(-) VSMC showed greater growth responses to platelet-derived growth factor and basic fibroblast growth factor, indicating that Agtr2(-) cells exhibit a generalized exaggerated growth phenotype. We studied the mechanism responsible for this phenotype and observed that extracellular signal-regulated kinase (ERK) activity was higher in Agtr2(-) VSMC at baseline and also in response to serum. ERK kinase inhibitor PD98059 inhibited both growth and ERK phosphorylation dose-dependently, while the regression lines between growth and ERK phosphorylation were identical in Agtr2(+) and Agtr2(-) VSMC, suggesting that increased ERK activity in Agtr2(-) VSMC is pivotal in the growth enhancement. Furthermore, the difference in ERK phosphorylation between Agtr2(+) and Agtr2(-) was abolished by vanadate but not by okadaic acid, implicating tyrosine phosphatase in the difference in ERK activity. These results suggest that the AT2 receptor expression during the fetal vasculogenesis influences the growth phenotype of VSMC via the modulation of ERK cascade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tsutsumi, Y., Matsubara, H., Masaki, H., Kurihara, H., Murasawa, S., Takai, S., Miyazaki, M., Nozawa, Y., Ozono, R., Nakagawa, K., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7886 · Cited by 561
Angiotensin II Type 2 Receptor Signaling Attenuates Aortic Aneurysm in Mice Through ERK Antagonism
Habashi, J. P., Doyle, J. J., Holm, T. M., Aziz, H., Schoenhoff, F., Bedja, D., Chen, Y., Modiri, A. N., Judge, D. P., & Dietz, H. C. (2011) · Science · doi:10.1126/science.1192152 · Cited by 472
The Angiotensin II AT2 Receptor Is an AT1Receptor Antagonist
AbdAlla, S., Lother, H., Abdel-tawab, A. M., & Quitterer, U. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105253200 · Cited by 463
Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension
Jeffery, T. K., & Morrell, N. W. (2002) · Progress in Cardiovascular Diseases · doi:10.1053/pcad.2002.130041 · Cited by 317
Karnik, S. S., Unal, H., Kemp, J. R., Tirupula, K. C., Eguchi, S., Vanderheyden, P. M. L., & Thomas, W. G. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.010454 · Cited by 302
Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide
Berry, C., Touyz, R., Dominiczak, A. F., Webb, R. C., & Johns, D. G. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.281.6.h2337 · Cited by 259
The AT2 receptor—A matter of love and hate
Steckelings, U. M., Kaschina, E., & Unger, T. (2005) · Peptides · doi:10.1016/j.peptides.2005.03.010 · Cited by 257
AT2 receptors: Functional relevance in cardiovascular disease
Jones, E. S., Vinh, A., McCarthy, C. A., Gaspari, T. A., & Widdop, R. E. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.08.009 · Cited by 237
“Consequently, it was originally believed that the AT2R was primarily involved in cellular growth and differentiation (Capponi, 1996; Akishita et al., 1999; Yamada et al., 1999).”
BackgroundAngiotensin AT2 receptors: cardiovascular hope or hype?
Widdop, R. E., Jones, E. S., Hannan, R. E., & Gaspari, T. A. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705448 · Cited by 223
“Conversely, foetal VSMC from AT2R-null mice demonstrate a generally enhanced growth phenotype, as well as increased basal- and serum-induced ERK phosphorylation levels (Akishita et al., 1999).”
BackgroundZambidis, E. T., Soon Park, T., Yu, W., Tam, A., Levine, M., Yuan, X., Pryzhkova, M., & Péault, B. (2008) · Blood · doi:10.1182/blood-2008-03-144766 · Cited by 196
The angiotensin II type 2 receptor: an enigma with multiple variations
Gallinat, S., Busche, S., Raizada, M. K., & Sumners, C. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.278.3.e357 · Cited by 174
“(1) studied cell cultures derived from wild-type and AT2 receptor-deficient mice.”
BackgroundThe Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target
Steckelings, U. M., Widdop, R. E., Sturrock, E. D., Lubbe, L., Hussain, T., Kaschina, E., Unger, T., Hallberg, A., Carey, R. M., & Sumners, C. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000281 · Cited by 97
Tornling, G., Batta, R., Porter, J. C., Williams, B., Bengtsson, T., Parmar, K., Kashiva, R., Hallberg, A., Cohrt, A. K., Westergaard, K., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101152 · Cited by 54
Wilms, H., Rosenstiel, P., Unger, T., Deuschl, G., & Lucius, R. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505040-00004 · Cited by 52
Metadata
- Authors
- Akishita, M., Ito, M., Lehtonen, J. Y. A., Daviet, L., Dzau, V. J., & Horiuchi, M.
- Venue
- Journal of Clinical Investigation
- Published
- 1999-01-01
- Volume
- 103
- Issue
- 1
- Pages
- 63-71
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2114938192
- Cited by
- 100
- References
- 0
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.